Kezar Life Sciences – (KZR, +N, 23-Mar-22)
Franklin Berger (Non-Executive since 2016) purchased $1.3 million of stock at $16.25 on March 21st, increasing his holding by 10%. This is his first open-market purchase and its size is larger than his two previous subscriptions combined in February and June 2020 at $2.60 and $5.50 respectively.
He has a very good record in Essa Pharma Inc, another pharmaceutical company where he is a director, and made an equally large purchase in August 2020 which was extremely well-timed. The stock has more than doubled over a year and this is interesting to see him making this large purchase.
We are ranking the stock +N.